Загрузка...
Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration
OBJECTIVE: Plasma interleukin-1 beta (IL1β) may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist (rhIL1RA) did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of rhIL1RA by baseline plasma IL1β or IL1RA concentration....
Сохранить в:
| Опубликовано в: : | Crit Care Med |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5734955/ https://ncbi.nlm.nih.gov/pubmed/28991823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000002749 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|